李华飞，男，海军军医大学肿瘤学博士，免疫学博士后，曾任中国人民解放军海军某部军医、南京军区南京总医院肿瘤科医师，主要围绕纳米医学及恶性肿瘤的靶向治疗展开研究，致力于将纳米技术应用于靶向治疗药物的改造，在相关研究领域取得了一系列具有原创意义的代表性科研成果，以第一作者或通讯作者发表SCI论文10篇，以项目负责人主持或参与包括国家自然科学基金、国防科技基础加强计划技术领域基金项目、上海市“一带一路”青年科学家交流项目等多项科研基金。
电话：**
邮箱：lihuafei@shu.edu.cn
教育与工作经历：
2001.9-2006.6：第二军医大学，学士（临床医学）
2006.7-2008.6：中国人民解放军海军南海舰队某部，军医
2008.7-2009.8：南京军区南京总医院肿瘤内科，医师
2009.9-2012.6：第二军医大学，硕士研究生（肿瘤学）
2012.9-2015.6：第二军医大学，博士研究生（肿瘤学）
2015.6-2015.10：中国人民解放军南部战区海军某部，主治医师
2015.10-2019.4：海军军医大学（第二军医大学），博士后（免疫学）
2019.5-至今：上海大学生命科学学院，副教授
主要研究领域：肿瘤靶向治疗与纳米医学
近五年代表性论文：
(1). Huafei Li^#,*, Hai Jin^#, Wei Wan^#, Cong Wu, Lixin Wei*, Cancer nanomedicine: mechanisms, obstacles and strategies, Nanomedicine, 2018, 13(13), 1639–1656. (First author, Corresponding author)
(2). Cong Wu^#, Wei Wan^#, Ji Zhu, Hai Jin, Tiejun Zhao*, Huafei Li*, Induction of potent apoptosis by an anti-CD20 aptamer: Via the crosslink of membrane CD20 on non-Hodgkin's lymphoma cells, RSC Advances, 2017, 7:5158-5166. (Corresponding Author)
(3). Fan Zhang^#, Junlan Yanga^#, Huafei Li^#, et al. Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. Oncoimmunology, 2016, 5(5): e**. (Co-first author)
(4). Huafei Li, Yun Sun，Di Chen，et al, Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity, Scientific Reports, 2015, 5:15712-15725. (First author)
(5). Hua-Fei Li^#*，Cong Wu^#，Ting Chen^#，et al，Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity，International Journal of Nanomedicine，2015, 10:4783-4796. (First author)
(6). Hua-Fei Li^#，Cong Wu^#，Mao Xia^#，et al，Targeted and controlled drug delivery using a temperature and ultra-violet responsive liposome with excellent breast cancer suppressing ability，RSC Advances，2015, 5(35):27630-27639. (First author)
(7). Huafei Li^#，Kun Guo^#，Cong Wu^#，et al，Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma，Chemical Biology & Drug Design，2015, 86(4):783-794. (First author)
(8). Huafei Li^#，Ge Zhang^#，Cheng Jiang^#，et al，Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster, Oncotarget, 2015, 6(27):24192-24204. (First author)